A5078286163- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Asthma and respiratory diseases
- Sarcoidosis and Beryllium Toxicity Research
- Eosinophilic Disorders and Syndromes
- Heart Rate Variability and Autonomic Control
- Palliative Care and End-of-Life Issues
- Health and Wellbeing Research
- Medical and Biological Sciences
- Traumatic Ocular and Foreign Body Injuries
- Cardiovascular and exercise physiology
- Health, psychology, and well-being
- Autopsy Techniques and Outcomes
- Restraint-Related Deaths
- Systemic Sclerosis and Related Diseases
- Health disparities and outcomes
Boehringer Ingelheim (Japan)
2015-2022
Boehringer Ingelheim (Philippines)
2015
The University of Tokyo
2012-2013
Background: The efficacy and safety of once-daily tiotropium + olodaterol (T+O) maintenance treatment was demonstrated in the large, multinational, replicate, randomized, Phase III, Tonad ® 1 (NCT01431274) 2 (NCT01431287) studies patients with moderate to very severe COPD. However, there may be racial differences effects T+O on lung function Methods: In this Tondao subgroup analysis, we assessed Japanese participants. Results: Versus overall population, 413 randomized treated were slightly...
The efficacy of nintedanib in progressive fibrosing interstitial lung diseases (ILDs) was demonstrated the randomised, double-blind, placebo-controlled INBUILD trial. This subgroup analysis evaluated and safety Japanese population.Patients with ILDs (evaluated by physicians within 24 months screening) were randomised (1:1) to twice-daily 150-mg or placebo; treatment continued until last patient completed 52 weeks. primary endpoint annual rate decline forced vital capacity (FVC) over...
To understand assumptions about and approaches to interstitial lung disease (ILD), including those of the progressive phenotype (progressive fibrosing ILD), this multinational survey assessed physicians' attitudes toward, knowledge of, management strategies for ILD.This internet-based physicians was conducted between November 2018 February 2019. Practical ILD, current assessment treatment were compared countries/regions (Japan vs. United States European Union) specialties (pulmonologists...
A previous subgroup analysis of data from the INBUILD trial showed that nintedanib reduced annual rate decline in forced vital capacity (FVC) Japanese patients with progressive fibrosing interstitial lung diseases (PF-ILDs). The safety profile over 52 weeks was similar to overall population. Using 108 PF-ILDs who had received at least 1 dose study medication trial, we evaluated effect on disease progression and assessed whole period (i.e., a longer duration than prior analysis) compared...
Background: Olodaterol is a novel long-acting β 2 -agonist with proven ≥24-hour duration of action in preclinical and clinical studies. Objective: This randomized, double-blind, placebo-controlled, parallel-group study evaluated the dose response once-daily (QD) olodaterol based on bronchodilator efficacy, safety, pharmacokinetics over 4 weeks Japanese patients chronic obstructive pulmonary disease (COPD). Methods: All eligible were randomized to receive µg, 5 or 10 µg placebo for via...
【緒言】救急領域における医療者と患者遺族との関わりにつき，医師を対象とした実態調査は行われてこなかった。救急医による遺族対応の実態や意識を明らかにし，救急医療における遺族対応のあり方を検討するため質問紙調査に基づく研究を行った。【対象】2011年2月現在での日本救急医学会救急科専門医3,049名を対象とした。【方法】所属機関内における研究倫理審査委員会の承認の他，倫理的配慮を講じた上で，無記名・自記式・郵送式の質問紙調査法として用い，回答結果につき統計解析を行った。【結果】860名の救急科専門医より回答があり，有効回答率は28.5%であった。遺族対応に積極的に取り組もうとしている医師は，そうでない医師に比べ遺族に説明する際の通常の説明項目に配慮が配られていた他，遺族が遺体と対面する際の項目にも幅広く留意がなされている傾向がみられた。調査対象者である救急科専門医のうち4割近くが遺族対応に関する専門の研修を受けたいと回答していた。遺族対応に関する専門研修を望む群では，自殺者，多発・高度損傷受傷者など一定の場合において，遺族への対応に苦慮しているということも判明した。また9割近くの回答...